The algorithm will see you now? Patients say not without a doctor nearby

AI may be reshaping modern medicine, but when it comes to health, patients still want to know a real person is watching the screen

5:00 AM

Author | Jared Wadley

real hand touching robot hand connecting in middle
Michigan News

This story was originally published by Michigan News. 

Researchers at the University of Michigan and Michigan State University found that United States adults were significantly more likely to trust in and choose medical AI in scenarios with better AI performance, U.S. Food and Drug Administration approval, national and local certifications, the presence of a clinician, and the use of representative data.

The federally funded study, which appears in JAMA Network Open, is important because it underscores a central challenge for health systems: To build trust in medical AI, institutions must prioritize performance and transparency while balancing governance and the enduring importance of the clinician-patient relationship.

Rather than simply asking patients what they value, the study measured how specific features influenced choices, revealing that AI accuracy outweighed every other attribute.

“The advantage of a study like this is that it captures patients’ choices, rather than just what they say is important in the abstract,” said Ana Bracic, lead author and assistant professor of political science at Michigan State University.

In a national survey of 3,000 adults conducted in December 2024, respondents weighed in on hypothetical AI-assisted medical visits.

They repeatedly chose between paired diagnostic scenarios that varied by six features, including AI performance level, the presence of a clinician, federal or institutional oversight, and the quality of data used to train the system. In total, they evaluated 12 mock visits each, generating 36,000 observations.

The study sample reflected a broad cross-section of U.S. adults, with participants spanning age, race, income and education levels.

When AI systems were described as performing at or above the level of medical specialists, participants were dramatically more likely to select those visits, boosting the probability of choosing that option by up to 32.5%.

The patients gravitated toward AI that outperformed general practitioners and matched or exceeded specialists, says co-author Kayte Spector-Bagdady, the George E. Wantz Research Professor of Bioethics at U-M.

But accuracy alone wasn’t enough.

The presence of a clinician—a “human in the loop”—increased the likelihood of choosing a visit by 18.4%.

Patients still wanted reassurance that a trained professional is overseeing their care.

But co-author Nicholson Price, U-M professor of law, warns that even though clinicians are important to patient trust, they won’t always be available as much as patients might like.

“Health systems engaged in local governance also shouldn’t assume that clinicians will always be trained, or have the time, or have the skill, or even be available at all, to perform governance tasks at the level of the individual patient encounter,” he said.

That said, performance mattered more to participants than a human in the loop—an interesting area for future policy exploration, Price says.

Oversight also mattered.

Participants preferred AI systems that had formal oversight, whether through FDA approval, Mayo Clinic certification or local hospital validation.

And when respondents were told the AI had been trained on representative, high quality data, they were more likely to favor that option as well.

Participants cited performance and clinician involvement as the primary reasons for their choices.

Many respondents expressed comfort with AI as a tool—but not as a standalone decision-maker.

The results of the research suggest that public acceptance of medical AI may hinge less on abstract enthusiasm for innovation and more on visible safeguards and demonstrated effectiveness, the researchers says.

“Patients appear willing to embrace AI—especially when it performs at a high level—but they are far more comfortable when it operates within a system that includes both oversight and human judgment,” they wrote.

The study’s authors also included U-M law students Sophie Towle and Rina Zhang, and Cornelius James, U-M assistant professor of internal medicine.

The research was primarily funded by a partnership between the Michigan Institute for Data & AI in Society and the U-M Institute for Healthcare Policy & Innovation.


More Articles About:

Artificial intelligence (AI) Future Think All Research Topics humanities
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story

University of Michigan block M logo

Nicholson Price

Professor

profile-kayte-spector-bagdady.jpg

Kayte Spector-Bagdady, JD, MBE

Associate Professor

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Purple shaded illustration of doctor listening to heart of patient on a bed
Health Lab

The AI is listening: Implications of machine generated clinical notes on health care

Michigan Medicine experts argue that use of artificial intelligent scribes during health care visits should be more carefully examined .
pattern up close sequencing gene navy yellow
Health Lab

Comprehensive DNA sequencing reveals hidden drivers of cancer

Two research papers describe how long-read nanopore sequencing can detect alterations in cancer cells that might be missed by conventional sequencing.
cancer cell blue yellow
Health Lab

‘Molecular glue’ stabilizes protein that inhibits development of non-small cell lung cancer and uterine cancer

University of Michigan researchers found a new protein target PP2A and developed a drug to treat non-small cell lung cancers that have KRAS mutations.
Two older women looking at the Medicare website on a laptop screen
Health Lab

Many older adults make Medicare decisions quickly and most don’t change plans, poll finds

Sixty percent of older adults spend less than an hour choosing their Medicare coverage during Open Enrollment, a new poll finds.
pills close up some powder some round some long
Health Lab

What’s the latest on 7-OH and kratom availability and addiction care?

The United States Drug Enforcement Agency has announced it will place non-botanical products containing 7-OH on Schedule I, joining three other synthetic opioids, effectively removing them the market, leaving natural leaf kratom available amid a shortage of addiction treatment providers.
scratching arm pink sweater in living room teal couch
Health Lab

A metabolic “switch” that could help reset scar-producing cells in scleroderma

Researchers at University of Michigan Health and collaborating institutions have identified a metabolic enzyme that may offer a fundamentally new way to attack one of the most difficult-to-treat features of systemic sclerosis, or scleroderma: progressive and potentially life threatening tissue scarring.